Physician profile
Delise Bailey
NPI 1457095705
$939.78
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $465 · 2023: $260 · 2024: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $220.35 | 2022-2024 | |
| Novo Nordisk INC | $123.87 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $109.62 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $98.90 | 2022-2023 | Mounjaro, Trulicity |
| Biohaven Pharmaceutical Holding Company LTD. | $69.93 | 2022 | |
| Medtronic, INC. | $50.65 | 2023 | Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $44.10 | 2022 | |
| Dexcom, INC. | $42.19 | 2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $33.82 | 2024 | Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.39 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.46 | 2022 | |
| Abbvie INC. | $20.70 | 2022 | |
| Merck Sharp & Dohme LLC | $20.17 | 2022 | |
| Nevro Corp. | $18.68 | 2023 | Senza |
| Exact Sciences Corporation | $15.73 | 2023 | Cologuard Collection Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Fusion Solutions, LLC | $15.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delise Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.